5 ESSENTIAL ELEMENTS FOR ABBV-744 DRUG DEVELOPMENT PROGRESS AND TIMELINE

In Phase C, participants will get ABBV-744 and oral navitoclax. In Section D, participants will obtain ABBV-744 and ruxolitinib. Contributors will receive treatment until finally condition progression or maybe the individuals are not able to tolerate the study drugs.There may be larger treatment stress for individuals in this trial when compared wi